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Abstract We introduce how biophysical modeling in pharmaceutical research and
development, combining physiological observations at the tissue, organ and system
level with selected drug physiochemical properties, may contribute to a greater and
non-intuitive understanding of drug pharmacokinetics and therapeutic design. Based
on rich ﬁrst-principle knowledge combined with experimental data at both con-
ception and calibration stages, and leveraging our insights on disease processes and
drug pharmacology, biophysical modeling may provide a novel and unique
opportunity to interactively characterize detailed drug transport, distribution, and
subsequent therapeutic effects. This innovative approach is exempliﬁed through a
three-dimensional (3D) computational ﬂuid dynamics model of the spinal canal
motivated by questions arising during pharmaceutical development of one molec-
ular therapy for spinal cord injury. The model was based on actual geometry
reconstructed from magnetic resonance imaging data subsequently transformed in a
parametric 3D geometry and a corresponding ﬁnite-volume representation. With
dynamics controlled by transient Navier–Stokes equations, the model was imple-
mented in a commercial multi-physics software environment established in the
automotive and aerospace industries. While predictions were performed in silico,
the underlying biophysical models relied on multiple sources of experimental data
and knowledge from scientiﬁc literature. The results have provided insights into the
primary factors that can inﬂuence the intrathecal distribution of drug after lumbar
administration. This example illustrates how the approach connects the causal chain
underlying drug distribution, starting with the technical aspect of drug delivery
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DOI 10.1007/s10928-010-9184-ysystems, through physiology-driven drug transport, then eventually linking to tissue
penetration, binding, residence, and ultimately clearance. Currently supporting our
drug development projects with an improved understanding of systems physiology,
biophysical models are being increasingly used to characterize drug transport and
distribution in human tissues where pharmacokinetic measurements are difﬁcult or
impossible to perform. Importantly, biophysical models can describe emergent
properties of a system, i.e. properties not identiﬁable through the study of the
system’s components taken in isolation.
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Introduction
With approximately 130,000 new cases per year globally, spinal cord injury is a
global epidemic that typically involves males between the age of 16–30 in 82% of
cases [1]. While there is no fully restorative cure for spinal cord injury yet, several
new regenerative therapies targeting the spinal cord are being developed [1]. The
development of one of these molecular therapies, namely anti-Nogo-A antibodies
[2], has been the motivation for creating computational ﬂuid dynamics (CFD)
models to understand the pharmacokinetics (PK) of its delivery. The Nogo-A
protein is an endogenous major neurite growth inhibitor leading to restricted axonal
regeneration. Thus Nogo-A blockade with antibodies or peptides may enhance
compensatory sprouting and neurite outgrowth. The primary site of action for the
antibody is determined by Nogo-A expression on the cell surface of oligodendro-
cytes in the neighborhood of the injured section of the spinal cord which is typically
located in the upper thoracic or cervical levels of the spine. Access to the spinal
parenchymal tissue is challenged by the presence of inﬂammation due to the injury
and the general protective nature of the tissues that surround the brain and spinal
cord that keep foreign substances out. Thus delivery directly into the cerebrospinal
ﬂuid (CSF) in the spinal intrathecal space is likely necessary for these compounds.
A wealth of knowledge on delivery and PK of drugs targeting spinal cord function
has been developed most notably with local anesthetics and opioids that are typically
administered into the CSF in the spinal subarachnoid space by intrathecal injection or
infusion at the lumbar site [3]. These agents are typically administered near the
region where pharmacological effect in the spinal cord is needed, with the objective
not to have the effect spread far from the administration site, particularly towards the
upper regions of spinal cord and brain. Conversely, in cases like spinal cord injury
where the relevant receptor target is located in the upper thoracic, the cervical, or
even the brain region, a precise understanding of the inﬂuence of anatomy and
physiology on pharmacokinetics is needed to optimize drug administration and
provide drug distribution at this target site of pharmacologic action.
When modeling the pharmacokinetics of a drug administered intravenously in the
systemic circulation, it is often assumed to be instantly well stirred within the
central distribution volume, that it will reach its target site by rapid vascular
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123delivery and local diffusion, and that the processes of distribution and clearance will
decrease drug concentration in a ﬁrst order manner over time. These underlying
assumptions enable description and understanding of systemically administered
drugs with classical (compartmental) PK modeling approaches. In contrast,
molecular transport and PK in non-well-stirred, oscillating ﬂuid systems like the
CSF following intrathecal drug administration may not be well described by
classical PK modeling approaches due to poor validity of the assumptions above,
which are normally reasonable for many drugs that show linear pharmacokinetics. A
limitation to understanding human intrathecal PK of spinal cord injury therapies is
imposed by intrinsic experimental difﬁculties and strong clinical restrictions to the
number of and location where CSF samples can be taken, making direct and precise
experimental observations possible only rarely at the lumbar site.
These differences motivate a series of questions for the pharmacometrician to
address. What is the drug concentration proﬁle in the cervical spine region,
following lumbar injection? Is there a distribution difference if the same dose is
administered by slow infusion or instantaneous bolus injection? What are the most
important factors affecting intrathecal distribution? Where does the rest of the drug
go? One alternative way to approach these questions is offered by the application of
biophysical modeling of the spinal CSF system. Based on rich ﬁrst-principle
knowledge of ﬂuid ﬂow combined with experimental data at both conception and
calibration stages, biophysical modeling may provide a novel and unique
opportunity to interactively characterize detailed drug transport, distribution, and
subsequent therapeutic effects in the CSF. Relying on the principles of momentum
and mass conservation (Navier–Stokes equations) [4], a commercial multi-physics
software environment established in the automotive and aerospace industries was
used to understand the factors that contribute to drug distribution after injection into
the intrathecal space.
After a brief introduction into the physiology of the cerebrospinal ﬂuid system,
we present the new methodology as well as the key mechanisms acting as driving
forces on the ﬂuid system that impact CSF pharmacokinetics. We conclude with an
example of a detailed investigation of the intrathecal injection process, followed by
a drug distribution simulation along the spinal CSF space over several hours, which
at this stage might be considered as the two most immediate and useful model-based
applications within the pharmaceutical drug development process.
Development of the CSF biophysical model
Theoretical and experimental constraints
Classical (compartmental) pharmacokinetic modeling of drug distribution in the
cerebrospinal ﬂuid is hampered by the assumptions underlying the method and is
affected, particularly during the model-building phase, by the practical limitations
in measuring drug concentration in the CSF along the spinal canal with sufﬁcient
frequency after injection. The general assumption of modeling compartments with
spatially homogenous concentration of drug, while practically not accurate,
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administration that are representative of what one sees when measuring concen-
tration levels in the blood. This is not necessarily the case for concentrations
measured in the CSF, as noted by Kern et al. [5] in an analysis of the intrathecal
pharmacokinetics of a peptide administered in a preclinical animal model. The
temporal distribution pattern could be described by a series of exponential terms but
equating the exponential terms to volumes and clearances did not result in values
that had physiologic meaning.
Additionally, since access to the CSF is limited, the ability to sample the space to
make measurements is a challenge. With the exception of speciﬁc experimental
preclinical models where multiple catheters for drug delivery and concentration
sampling can be made, the investigator is generally restricted to sample drug from
the same catheter or needle that was used to deliver the drug. This can lead to
sample contamination and relies on relatively fast drug dispersal after the injection.
Otherwise, the sampling to measure the concentration could be the primary means
by which drug leaves the CSF producing an artifact on the estimates of drug
elimination from the space.
Because the CSF can be thought of as a closed space to some degree that is at
positive pressure relative to other spaces in the body, ﬂuid ﬂow is impacted by
punctures to the integrity of the dura, to positional changes of a patient, and a
number of other physical factors which have been documented in clinical trials
primarily with intrathecal anesthetic agents [6–8]. Despite these challenges, it is still
important to understand what inﬂuences the duration and extent of drug exposure in
the spinal subarachnoid space after intrathecal administration, which motivated our
exploration using a computational ﬂuid dynamics approach.
From system anatomy to model geometry
Along the spinal column, the spinal cord and the CSF cavity are protected by the
bones of the vertebral spine. The epidural space and the venous plexus are located
in-between the vertebrae and the dura mater, which is the outermost resilient
membrane covering the brain and the spinal cord. A middle layer (arachnoid mater)
and the innermost membrane (pia mater) surround the brain, spinal cord and nerve
roots. The CSF cavity in-between the arachnoid and dura mater is crossed by the
outgoing nerve roots and various membranous elements in the posterior spinal
subarachnoid space [9]. The shape of the spinal subarachnoid space is driven by the
internal ﬂuid pressure and its membrane structure, and by the surrounding bones and
the epidural space [10]. This results in a non-homogenous annular volume with
enhanced ﬂuid space in the cervical and lumbar region, as well as a reduced cross-
sectional diameter in the thoracic area [9].
The geometric model of the spinal subarachnoid space was based on data
published in [11]. The region of interest in the current model was from cervical 1
(c1) to lumbar 2 (l2) (Fig. 1a, b). Cross-sections of the spinal subarachnoid space
were approximated as elliptically-shaped areas that were connected via an axial
spline. The area mesh was extruded along the dura and pia mater in the transverse
direction, in order to get a hexahedral volume mesh. Additional local reﬁnements
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special physical conditions (e.g., lumbar injection region). Based on the results in
[12], connective tissues, nerve roots and blood vessels (which form a meshwork
within the spinal subarachnoid space) [9] were neglected in the current model.
From system physiology to model dynamics
The CSF, essentially an ultra-ﬁltrate of the blood, surrounds the brain and spinal
cord. CSF is produced mainly by the choroid plexus in the brain ventricles with a
daily production rate of about 500 ml in humans [13]. The total volume of the CSF in
humans is 170 ml on average, of which approximately 33% is found intracranially
within the brain ventricles [14]. This volume shows large interindividual variability.
From the ventricles, it ﬂows through the foramina of Luschkae and the foramen of
Magendie. A small percentage of CSF leaves the cranial space and enters the spinal
subarachnoid space. Most of the CSF ﬂows along the convexities of the surface of the
brain toward the arachnoid granulations where it gets absorbed back into the venous
circulation [13]. We approximated volume of the spinal canal to 50 ml.
The CSF motion in the spinal subarachnoid space may be described by a system
of partial differential equations that conserve mass and momentum. The transient
three-dimensional Navier–Stokes equations (Eqs. 1, 2) were solved with viscous
Fig. 1 T2-weighted magnetic resonance images of the intact (a) and injured (c; C6/C7 dislocation)
spinal cord; and (b) 3D reconstruction of the spinal CSF space used as model geometry
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123terms and molecular diffusion, using ﬁnite-volume (FV) computational ﬂuid
dynamics. Computations were performed using a commercial FV CFD solver,
Starcd 3.26 (CD-Adapco).
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Under normal physiological conditions, the CSF behaves as an incompressible
Newtonian ﬂuid with the density and viscosity of water at 37C. The diffusion
constant of the drug compound investigated with this model (monoclonal antibody)
was obtained from reference [15]. Biophysical parameters and dependent variables
are listed in Table 1.
In the presented isotropic version of the Navier–Stokes equations, the density q
and the cartesian velocity components u, v and w determined the mass conservation
Eq. 1. In addition the pressure p and the viscous shear stress tensor sij as well as the
external acceleration forces fi (e.g. gravity) were taken into account in the
momentum conservation Eqs. 2a–2c.
Driving forces
In addition to CSF circulation, production and absorption in the cranium, the spinal
CSF dynamics are mainly driven by the pressure variation related to blood pulsation
in the brain, as well as intrathoracic pressure variation generated by the diaphragm
contraction in the abdominal space during breathing [16–18]. These two driving
forces for ﬂuid ﬂow in the spinal canal were implemented in the model.
Table 1 Model parameters and
variables Biophysical model parameters
q (kg/m
3) Density (37C) 993.2
D( m
2/s) Diffusion coefﬁcient (from [15]) 4.3e
-11
fi (m/s
2) External acceleration vector (gravity) [0, 0, -9.81]
Dependent variables
u, v, w (m/s) Velocity components in x, y, z
p( Pa) Pressure
sij (Pa) Viscous shear stress tensor
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123The brain is supplied by arterial inﬂow and venous outﬂow. Since the cranium is
nearly rigid, the pulsation in blood ﬂow must be accounted for. According to the
Monro-Kellie hypothesis, this may be achieved via creating a compliant spinal canal
[19]. As a result, an oscillating in- and outﬂow from/to the spinal canal is obtained.
Alperin et al. [20] determined the transient mass ﬂow proﬁle in the cervical
subarachnoid space of healthy volunteers and patients with Chiari malformation.
The CSF velocities were obtained by velocity-encoded MRI. The cross-sectional
averaged mass ﬂow in the cervical region was applied as a periodic inlet condition
representing the cranial blood volume changes.
The second driving force is a consequence of breathing [21]. With inhalation, the
diaphragm increases the pressure in the abdomen; this also increases the venous
pressure in the epidural space. The increased pressure leads to a compression of the
spinal canal. In the current model, compression and expansion of the spinal
subarachnoid space were implemented by moving the boundary of the space and by
compressing the ﬁnite-volume mesh using a moving grid approach. The transient
movement of the subarachnoid space acts like a second lower frequency pumping
source for CSF transport.
The solution of the Navier–Stokes equations using the above-mentioned
boundary conditions resulted in an oscillating ﬂuid ﬂow in the spinal canal. Peak
ﬂuid velocities on the order of 10 mm/s were obtained. Figure 2 shows velocities as
vectors in a cross-section of the spinal canal (left: max amplitude caudal, right: max
amplitude cranial).
Although the present calculations did not impose a net mass ﬂow over the
boundaries, a non-zero mean ﬂow was obtained in the channel. Oscillatory ﬂow
inside complex geometries such as the annular volume of the spinal channel, with
varying non-concentric cross-sections in the axial direction, may indeed generate
secondary ﬂow regions, a phenomenon known as steady streaming. Gaver and
Grotberg described steady streaming in a tapered channel [22]. The effect of steady
streaming resulting from an oscillating ﬂow ﬁeld on the given geometry is
illustrated in Fig. 3.
Simulating CSF motion
Transient simulations of oscillating ﬂuids are computationally intensive. In the
example described here, the computation of a single heart beat cycle would typically
require over 12 h using a 2 Intel Xeon X5482 processor (12 MB cache, 3.2 GHz,
1600 MHz FSB). The reason for this is that impulse and mass conservation
equations need to be solved for every oscillation cycle, which requires high
resolution, both temporally and spatially. Hence, for the determination of
concentration proﬁles several hours after an injection into the CSF, the method
described above was not realistically applicable. Under the assumption that the
pulsations are periodic, we determined the transport by steady streaming in one
breathing cycle. With that we calculated the steady streaming velocity ﬁeld, which
was then kept constant (‘‘frozen ﬂow ﬁeld’’). Based on this frozen ﬂow ﬁeld, the
molecular diffusion equation was solved, to determine molecular drug transport
along the spinal space. The magnitude of steady streaming and the resulting drug
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order of 0.1 mm/s, yet faster than molecular diffusion of large molecules such as
monoclonal antibodies (MW *150 kDa). This value was in general agreement with
results from Di Chiro et al. [23] who showed that radiolabeled albumin injected into
the lumbar CSF ascends the length of the spine to the base of the brain within 1 h. In
Fig. 2 Maximum velocity ﬂow proﬁle in (a) caudal and (b) cranial direction at T10 during an oscillating
ﬂow simulation driven by pulsating pressure changes in the cranium and the abdominal space (contour
plot of velocity magnitude shown on the complete cross-section, vector plot represented on a reduced
subset of elements in the symmetry plane)
Fig. 3 Simulation of drug transport starting at T11 (a) and propagating caudal in the lateral and cranial
in the posterior and anterior region for ﬁve (b) and 10 s (c) using a steady streaming vector ﬁeld
previously determined by an oscillating ﬂuid ﬂow simulation (scaled to 50% of the initial concentration)
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123order to match this transport velocity, the wall motion amplitude, which generates
the breathing oscillation, was adjusted accordingly.
Applications of the biophysical model to better understand intrathecal
pharmacokinetics
The biophysical model of the spinal CSF space described above allowed for the
investigation of the principal transport mechanisms, a detailed analysis of injection
and infusion processes, as well as the approximation of molecular drug concen-
tration levels at certain time points post-injection. Two processes which are
particularly relevant from a pharmacokinetic point of view: (i) an injection analysis,
and (ii) a drug distribution simulation following a bolus injection are useful for
illustrating insight from this modeling approach.
Intrathecal drug injection
In the context of a drug development project involving intrathecal administration of
an anti-Nogo-A antibody at the lumbar level, we investigated the inﬂuence of both
the needle injection angle and the administration rate on the concentration
distribution and ﬂow dynamics, during bolus injection. To this end, a submodel was
created, focusing on the lumbar and lower thoracic regions with an additional inlet
located at the level of L1-2 on the dura mater wall. To cope with the ﬂuid dynamics
generated by the injection jet, the computational grid within the injection region was
reﬁned, and a turbulence model (standard k-e-model) was introduced in this
area [24]. Figure 4 visualizes the simulation results following an injection rate of
Fig. 4 Simulation of an intrathecal injection (ﬂow rate: 0.3 ml/s) at lumbar site L2 based on an
oscillating CSF ﬂow (a) 1 s and (b) 3 s after the start of the injection
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1230.3 ml/s and an injection angle of 45. Local concentrations and the range of
distribution in the oscillating CSF for different types of injection were characterized
quantitatively in this manner.
In addition, the resulting drug distribution patterns could be used as a starting
point for the determination of drug concentration levels at different positions along
the spinal cord and over time.
Computing spinal drug distribution kinetics
The initial concentration distribution simulated above was now applied on the
steady-transport ﬁeld (steady-streaming). This is visualized for t = 0 min,
t = 10 min and t = 20 min, on an 11 cm segment of the lower thoracic lumbar
region in Fig. 5.
The method described above was used to determine drug concentration levels
within the complete canal over several hours. As an example, Fig. 6 shows the
averaged concentration at different positions of the spinal subarachnoid space
within the ﬁrst hour after administration (right). In addition the contour plot (left
side of the ﬁgure) illustrates the three-dimensional aspects of the distribution
process 60 min after injection.
In the present simulations, neither drug binding to its receptor target nor drug
metabolism was assumed. Both may nevertheless be considered as contributing to
drug elimination in the CSF, via additional equations that can be integrated into the
model. To address the ﬁnal question regarding where the rest of the drug goes that
enters the lower lumbar and sacral CSF space, an additional feature that estimated
Fig. 5 Three-dimensional drug propagation in the lower thoracic lumbar region starting from a
concentration distribution simulated in a separate injection analysis (a). The contour plots (scaled to 50%
of the initial concentration) after 10 min (b) and 20 min (c) show decreased and homogenized drug
concentration levels
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of ﬂuid in this space was not explicitly included due to lack of literature data to
inform the model. This missing information was determined during experimental
validation to be applied in the future.
Experimental validation
Since the computational model of CSF dynamics described here was developed
from ﬁrst principles based on the geometry of the spinal system and the physics of
CSF ﬂow, clinical literature was initially used for comparing the model predictions
to measured ﬂuid ﬂow.
To gain direct physiological insight for the modeling of the spinal CSF space, a
close collaboration with the MRI experts from the Division of Radiological Physics
at the Institute of Radiology, University Hospital Basel was established. The group
had previously developed a Breathing-ECG Synchronized System (BESSY) [25],
which could be adapted to separately measure blood pulsation and respiratory
inﬂuences on the CSF dynamics.
Fig. 6 Steady streaming based transport simulation of an initial concentration distribution (determined in
a separate injection analysis) in the spinal CSF (left: contour plot of the local concentration levels 60 min
after the injection (scaled to 10% of the initial concentration); right: averaged drug concentration proﬁles
from L2 to C4 within the ﬁrst hour post-injection)
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the cervical region due to intracranial pressure changes were in the same order as
what we determined in the cervical region using our model based on literature. As
mentioned, those measurements were already performed by Alperin et al. [20]o n
large numbers of healthy volunteers and were published with high temporal
resolution. In contrast, the amount of published data regarding the inﬂuence of
breathing on the CSF dynamics was limited.
Our assumption on the dura mater motion for the presented model was originally
based on information of CSF volume changes in the lumbosacral sac during
increased abdominal pressure investigated by Martins et al. [17], as well as the
transport measurements with radiolabeled albumin published by DiChiro et al. [23],
which could not be explained without the additional effects of abdominal pressure
changes due to breathing on the CSF dynamics. Using MRI image sequences of the
CSF motion caused by breathing in a small study of healthy volunteers enabled us to
reﬁne those rough assumptions and provide another essential contribution in the
understanding of the CSF dynamics.
For the planning of the experiments and the interpretation of the MRI sequences
of the complex in vivo ﬂuid oscillation, the biophysical model turned out to be a
powerful tool to combine, compare and understand the imaging results in the
environmental context. The 3D structure of the spinal CSF space in different
positions could be generated semi-automatically from 240 high-resolution image
slides. The resulting data from several velocity and tagging scans were applied and
analyzed based on the predictions from the model. As a result, several discrepancies
in the generated data could be identiﬁed and clariﬁed even before the ﬁrst ﬂuid
dynamic simulation of the complete system was started. This iterative investigation
led to the synthesis of two ﬁnal data sets of the spinal CSF space, based on two
healthy volunteers, which included geometries from C1 to S5, transient ﬂow
patterns in cervical, thoracic and lumbar regions, as well as approximate values of
the CSF dynamics generated during normal breathing. Velocity scans measured
using cine MRI at several sections of the spine provided calibration for the
simulated ﬂow dynamics.
Discussion and conclusions
We developed a 3D computational ﬂuid dynamics model of the spinal canal, based
on actual geometry reconstructed from MRI data and dynamics controlled by
transient Navier–Stokes equations. The iterative model-building process allowed for
a detailed investigation of the principal transport mechanisms observable in this
system. The results from this approach of using realistic anatomical features
coupled with biophysical principles of ﬂuid ﬂow dynamics and physiological
characteristics of the cerebrospinal system have offered insights into the primary
factors that can inﬂuence the intrathecal distribution of drug after lumbar
administration. By providing an industry-unique framework for appropriate
integration of biophysics ﬁrst principles and clinical data into a dynamic system
physiology platform, this technology allows for the simulation of different clinical
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next level.
Considering the limited number of CSF modeling examples in the literature and
the stringent safety and ethical restrictions on experiments and clinical trials related
to spinal cord injury, we were motivated to introduce a new quantitative assessment
method of drug distribution in the CSF to help assess results from preclinical
experiments and ongoing clinical trials, and combine them with physiological
observations at the level of tissue-organ-system interactions and selected physio-
chemical properties. The goal was to understand factors that could affect the
pharmacokinetics of a therapeutic antibody administered in the CSF, contributing to
a greater understanding of therapeutic delivery for spinal cord injury.
One clinically relevant question that we could approach with the biophysical
model described here was whether there is a practical distribution difference if the
same dose and volume is administered by slow (more than 60 s administration time)
or instantaneous (less than 60 s) bolus injection. Simulating these two administra-
tion scenarios revealed that initially the drug would move up the intrathecal space at
different velocities, and that the orientation of the drug delivery needle relative to
the CSF space would have an inﬂuence on axial dispersion of the drug, whereby
maximally laminar ﬂows would enhance axial dispersion of the injected drug and
more turbulent ﬂow would aid in circumferential dispersion [26]. However, when
projected in the time scale of hours, those local differences would tend to dissipate,
transport being dominated by the main driving forces of pulsation and breathing.
These insights guided the clinical team when deciding on the clinical parameters of
bolus administration to spinal cord injury patients enrolled in clinical trials,
substituting to prior human dosing experimentation which would have been
ethically difﬁcult if not impossible to perform.
In a meta analysis by Fettes et al., [27] of factors that contribute to the success of
spinal anesthesia, it was estimated that close attention to procedural detail by the
anesthesiologist is likely the distinguishing factor between patients who received
adequate spinal anesthesia and those who did not. Human clinical error can have a
large impact on spinal anesthesia results within a population of clinicians who are
commonly performing these types of treatments and assessments. Given that
clinicians that have great experience in this procedure still produce variable results,
there is need to better understand how drug is distributed throughout the CSF after
intrathecal injection and what steps, if any, clinicians can take to use this effective
drug delivery route more consistently.
The model of spinal CSF dynamics presented here allowed for the approximation
of molecular drug concentration levels in the cervical spine following lumbar
injection at certain time points post-injection as a function of biophysical, as well as
injection parameters. Thus, differences in distribution over hours following either
slow infusion or instantaneous bolus injection could be observed in the simulations
[28]. These results suggested that bolus injection would not lead to an inferior
distribution range compared to slow infusion. Because bolus injection delivers the
total amount of drug to the lumbar injection site almost instantaneously, driving
forces are likely to exert their effect on all drug molecules over a longer period of
time, therefore increasing the chance for the drug to reach distant (cervical) targets
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nature, provided the clinical team with useful conﬁdence when deciding for bolus as
the sole administration mode for later cohorts of ongoing clinical trials.
Predicting the amount of drug at a particular level of the spinal column after
administration is difﬁcult. Previous attempts to use classical pharmacokinetic
approaches for modeling drug delivery in the cerebrospinal ﬂuid have worked
reasonably well for describing the dose–response relationship when the target site of
drug effect is directly at the site of injection [29]. This has advanced the
understanding and utility of spinal anesthesia for instance. However, when drug
exposure after spinal administration occurs away from the site of injection, or the
anticipated dose-concentration-effect relationship does not appear to hold, the
limitations of the classical pharmacokinetic approach to spinal drug delivery
become apparent. The further away the pharmacological target is from the site of
administration, the more challenging it becomes to achieve a predictable concen-
tration for attaining clinical effect. Reasons behind these difﬁculties were recently
highlighted in an editorial by Drasner in the British Journal of Anaesthesia where he
very colorfully recounts August Bier’s initial clinical report of spinal anesthesia
with cocaine in 1899 [30]. Consistent in both Bier’s experiment and current clinical
practice is the problem of variability in clinical response that limits our knowledge
of cerebrospinal ﬂuid drug delivery.
This editorial accompanied an article by Ruppen et al. [31, 32] who provide data
from patients that received a spinal anesthetic that was either rated as successful
(complete anesthesia) or not and then assessed the concentration of bupivacaine, the
spinal anesthetic, to determine if a concentration—response relationship could be
indentiﬁed in the patients who did not produce complete spinal anesthesia. Their
results show that the range of concentrations one can measure from CSF is very
large (26–781 ng/ml in patients) and did not correlate with the success of the
anesthetic state. This provides further conﬁrmation that the intrathecal space does
not behave as a well mixed volume and that measuring concentration in the CSF
after injection to support a classical pharmacokinetic approach may not provide any
meaningful data for analysis, or information for clinical decision making.
What are the most important factors affecting intrathecal distribution? With the
challenges to interpreting the clinical data that exists for characterizing the dose-
concentration-effect relationship in spinally administered agents, our approach for
understanding the inﬂuence of biophysical forces on distribution appears to be well
motivated. By approaching the problem from ﬁrst principles, the contribution of
physiologic forces due to breathing and cardiac cycles was predicted as a primary
factor that allows a drug to distribute through the spinal canal. While this allows
axial spread of the administered agent, our results show that subtle factors such as
drug speed of injection, orientation of the injecting needle, and the amount of ﬂuid
administered will have a differentiating effect on the pattern of drug distribution in
the CSF. Given the variability that can occur in the CSF distribution, it is not
surprising that measured values within a population of patients may not have a
strong correlation to either the amount of drug given, the patient’s response to the
agent (if directly measurable like anesthesia) or to a number of other typical
covariates that are commonly used to adjust patient dosage.
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123These results provided evidence that allow us to assess the factors, which
contribute the most signiﬁcantly to variation in the overall distribution. Using
biophysics and properties of ﬂuid motion based on Navier–Stokes equations, allows
us to predict the general axial movement of drug within the CSF over time,
however, the amount of drug present at any particular spinal cord level is difﬁcult to
determine and not likely to be uniformly distributed throughout the level. This
provides considerable insight into the challenges of targeting drug delivery in the
CSF to a distant site from the injection location and gives us a means for assessing
ways to better reach our clinical target with therapeutic agents.
The reﬁned model, updated using ﬂow scans from MRI, allows us to address the
motivating question of this project to understand the inﬂuence of CSF dynamics on
the resulting drug concentration levels measured in sparse data from clinical trials.
After ﬁrst matching the model to the experimental transport results for big, non-
binding and stable molecules like albumin published by DiChiro et al. [23],
additional in vivo data of different-sized molecules with various target binding
afﬁnities will be fully integrated. Beyond the understanding of the principle
mechanisms and sensitivities of drug transport in the spinal CSF cavity, prediction
of individual dosing using imaging and computational methods could be feasible
using this approach. The necessary experimental investigations (e.g., Positron
Emission Tomography, MRI, etc.) as well as the extension of the model
functionality (molecule binding, metabolism, etc.) are currently in progress.
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